In today’s briefing:
- Wuxi Biologics (2269 HK): Mixed 1H23 Result; Strong Non-COVID Business Momentum Enhances Visibility
- Mirxes Pre-IPO: Early Signs of Commercialization Challenges
- Pfizer Inc: Delving into Their Game Plan For Future Growth! – Major Drivers
- NextGen Healthcare: What Is The Value That The Company Can Get From A Potential Sale?
- Vertex Pharmaceuticals: Exploring the Pipeline: From Pain Relief to Sickle Cell Miracles! – Major Drivers
Wuxi Biologics (2269 HK): Mixed 1H23 Result; Strong Non-COVID Business Momentum Enhances Visibility
- Wuxi Biologics (2269 HK) recorded 8% YoY revenue growth to RMB8.5B in 1H23. Strong momentum continued in the base business, with the non-COVID revenue achieving a 60% YoY growth.
- Ramping up of new manufacturing facilities, maintenance shutdown of existing facilities, slowdown in funding environment in China, and increasing expenses have negatively impacted the profitability.
- Total number of integrated projects reached a new record of 621 with 46 integrated projects added to the pipeline. As of June 30, backlog increased 9% YoY to $20.1B.
Mirxes Pre-IPO: Early Signs of Commercialization Challenges
- Mirxes, a Singapore-headquartered RNA technology company with a focus on cancer screening, plans to raise up to US$100m via a Hong Kong listing.
- In this insight, we examine its key product, GASTROClear’s technical and clinical data. We also look at the competitive landscape.
- We are of the view that the company’s product, despite improving the accuracy over incumbent competitors marginally, is not a killer product and will face challenges in ramping up sales.
Pfizer Inc: Delving into Their Game Plan For Future Growth! – Major Drivers
- Pfizer managed to surpass the revenue and earnings expectations of analysts.
- Operationally, non-COVID-19 revenue increased, but total revenue decreased in the quarter.
- The projected revenue declines in both PAXLOVID and COMIRNATY principally brought on this loss.
NextGen Healthcare: What Is The Value That The Company Can Get From A Potential Sale?
- This is a special one-time report on NextGen Healthcare (NASDAQ:NXGN) given the prevailing reports of the company exploring a sale.
- Amidst prevailing economic uncertainties, the healthcare sector is shining brightly as a hub of merger and acquisition (M&A) activities.
- NextGen Healthcare is at the heart of these discussions, given the recent flurry in its stock price, propelled by whispers of potential strategic shifts, including a possible sale.
Vertex Pharmaceuticals: Exploring the Pipeline: From Pain Relief to Sickle Cell Miracles! – Major Drivers
- Vertex Pharmaceuticals delivered a solid result and managed an all-around beat last quarter.
- The company’s continued momentum in all aspects, particularly in the Cystic Fibrosis (CF) business, has led to solid growth in global product revenue.
- Vertex has strategically invested in promising therapies for severe sickle cell disease, transfusion-dependent beta-thalassemia, acute pain relief, and CF treatments.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
